[Blood rheological effects in ischemic heart disease treated with antianginal and thrombolytic agents]

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Ischemic heart disease (IHD) involves complex hemorheological alterations.
• Understanding drug effects on blood viscosity and platelet function is crucial for IHD management.

Purpose of the Study:

• To investigate the impact of various antianginal and thrombolytic agents on blood viscosity, erythrocyte aggregation, and platelet behavior in IHD patients.
• To elucidate the role of hemorheological mechanisms in the therapeutic effects of these cardiovascular drugs.

Main Methods:

• Study included 161 patients with different forms of IHD.
• Assessed changes in blood viscosity, erythrocyte aggregation, and thrombocyte parameters during treatment.
• Evaluated effects of nitroglycerin, Sustac, micristin (aspirin/propranolol), verapamil, dipyridamol, trental, nonachlazin, sodium nitroprusside, and streptokinase (avelisine).

Main Results:

• Nitroglycerin and Sustac showed no significant hemorheological changes.
• Micristin and verapamil exhibited notable platelet disaggregational effects.
• Dipyridamol, trental, and nonachlazin improved erythrocyte function, reducing blood viscosity.
• Sodium nitroprusside transiently decreased platelet aggregation and blood viscosity.
• Streptokinase in acute myocardial infarction led to defibrinization, reduced aggregation, and lower blood viscosity.

Conclusions:

• Hemorheological mechanisms appear to play a significant role in the antianginal efficacy of the studied drugs.
• Different drug classes exert distinct effects on blood rheology and platelet activity.
• These findings highlight the importance of considering hemorheological profiles in cardiovascular drug selection and therapy.